Investors Business Daily·2d ago
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
Guardant Health is experiencing accelerating revenue growth, with Q2 2026 revenue up 44.3% year-over-year to $335.0M, driven by strong adoption of its liquid biopsy tests. Gross margins have expanded to 65.4%, but the company remains deeply unprofitable, with ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 44.3% year-over-year in Q2 2026, reaching $335.0M, while gross margin improved to 65.4%, but operating margin remained deeply negative at -38.5%.
Guardant Health's Shield blood test was added to the American Cancer Society's colorectal cancer screening guidelines, enhancing its market potential for average-risk adults.
The FDA approved Guardant360 CDx as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ER-positive breast cancer.
Guardant's InfinityAI and Guardant360 platforms provided real-world evidence supporting Japan's approval of ENHERTU for HER2-positive solid tumors, showcasing its clinical utility.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.90-18.1% vs -$0.76 | $335M+6.6% vs $314M |
Q2 2026 May 7, 2026 | -$0.85-5.5% vs -$0.81 | $302M+8.1% vs $279M |
Q1 2026 Feb 19, 2026 | -$1.00-30.4% vs -$0.77 | $281M+3.2% vs $272M |
Q4 2025 Oct 29, 2025 | -$0.74+6.3% vs -$0.79 | $265M+12.6% vs $236M |
Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Earnings and Valuation This table compares Guardant Health and
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) Director Alex Azar II sold 826 shares of Guardant Health stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director owned 825 shares of the
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark GH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Guardant Health, Inc. (GH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $177.16 | $23.49B | -53.36 | 32.88% | -42.39% | — | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — | |
| $15.88 | $830.15M | -6.56 | — | -194.74% | -41.33% | — | |
| $2.49 | $235.44M | 6.55 | 161.14% | 47.55% | 42.57% | — |
Guardant Health, Inc. (GH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Guardant Health, Inc. (GH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 18, 2026·SEC
May 7, 2026·SEC
Feb 19, 2026·SEC
Get notified when GH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Guardant Health, Inc. (GH) stock FAQ — growth, dividends, profitability & financials explained
Guardant Health, Inc. (GH) reported $1.18B in revenue for fiscal year 2025. This represents a 4586% increase from $25.2M in 2016.
Guardant Health, Inc. (GH) grew revenue by 32.9% over the past year. This is strong growth.
Guardant Health, Inc. (GH) reported a net loss of $453.4M for fiscal year 2025.
Guardant Health, Inc. (GH) had negative free cash flow of $240.7M in fiscal year 2025, likely due to heavy capital investments.
